The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2017 | An update on two trials evaluating venetoclax in subsets of CLL
John Seymour, MD, MPH from the Peter MacCallum Cancer Center, Melbourne, Australia, provides us an update on two trials evaluating venetoclax in the treatment of chronic lymphocytic leukemia (CLL) (NCT02966756) (NCT02005471). In CLL patients with 17p deletions, venetoclax was proven to be highly clinically effective and this was also shown in a long-term follow-up. Regarding the use of this novel agent in front-line therapy, there are currently trials for this underway, although currently there are no major updates on this. This video was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.
